Last reviewed · How we verify

NCT07381712

High-Flow Nasal Cannula Versus Non-Invasive Ventilation for Acute Respiratory Failure in Pulmonary Embolism.

Active, enrolled NA Last updated 2 February 2026
What this trial tests

NA trial testing High-Flow Nasal Cannula (HFNC) in Pulmonary Embolism in 100 participants. Participants enrolled and being followed up; not accepting new ones.

Timeline
1 October 2025
Primary endpoint
30 October 2026
30 November 2026

Quick facts

Lead sponsorAssiut University
PhaseNA
StatusActive, enrolled
Study typeINTERVENTIONAL
Allocationrandomized
Designparallel
Maskingsingle
Primary purposetreatment
Enrollment100
Start date1 October 2025
Primary completion30 October 2026
Estimated completion30 November 2026
Sites1 location across Egypt

Drugs / interventions tested

Conditions studied

Sponsor

Assiut University

Who can join

18 and older, any sex, with Pulmonary Embolism. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Acute pulmonary embolism (PE) often causes hypoxemic respiratory failure through ventilation-perfusion mismatch and right-ventricular (RV) strain; supportive oxygenation plus prompt anticoagulation are crucial to care . Current guidelines advise supplemental oxygen and escalation according to hemodynamic/respiratory status, but do not identify an optimal noninvasive modality for PE-related respiratory failure.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other trials of High-Flow Nasal Cannula (HFNC)

Trials testing the same drug.

Other recruiting trials for Pulmonary Embolism

Currently open trials in the same condition.

Other Assiut University trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07381712.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing